Brilaroxazine or placebo for schizophrenia: short- and long-term study
About this title
Read the official source — NCT05184335This study evaluates the safety and effectiveness of Brilaroxazine for people with schizophrenia.
Understand this study
What is this study about?
This study evaluates the safety and effectiveness of Brilaroxazine for people with schizophrenia.
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- Phoenix and 17 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 690
- Sponsor
- Reviva Pharmaceuticals
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug, Other
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05184335
- Official title
Show the full official title
Phase 3, Randomized, 28 Days, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Brilaroxazine (RP5063) in Subjects With Schizophrenia, Followed by a 52-Week Open-label Extension
Recruitment & locations
Phoenix · Bentonville · Little Rock
14 more locations
- Rogers
- Garden Grove
- Lemon Grove
- Riverside
- Hollywood
- Miami Lakes
- Atlanta
- Decatur
- Chicago
- Gaithersburg
- Boston
- Oklahoma City
- Austin
- Richardson
Interested in joining this study?
Questions about this study
What is this study about?
This study evaluates the safety and effectiveness of Brilaroxazine for people with schizophrenia.
Who is behind this study?
The study sponsor is Reviva Pharmaceuticals.
Does this study involve medication?
Yes. The study involves medication, including Brilaroxazine.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as recruiting.
